Baidu
map

J Med Case Reports:甲状腺全切术后的Graves病

2016-05-25 MedSci MedSci原创

甲状腺切除术后的甲状腺毒症主要是医源性的。较少见的是高功能甲状腺组织的残留或者异位甲状腺组织所致。研究人员报道的这一病例是非毒性甲状腺肿行甲状腺全切后出现持续7年的纵膈甲状腺导致的Graves病。一位67岁的白人妇女出现心悸,乏力,体重下降。她在60岁时因非毒性结节性甲状腺肿行甲状腺全切术,当时无恶变倾向。术后服用左旋甲状腺素100μg/天。她出现心动过速,无颈部肿块和眼部损害,促甲状腺素水平被抑

甲状腺切除术后的甲状腺毒症主要是医源性的。较少见的是高功能甲状腺组织的残留或者异位甲状腺组织所致。研究人员报道的这一病例是非毒性甲状腺肿行甲状腺全切后出现持续7年的纵膈甲状腺导致的Graves病。

一位67岁的白人妇女出现心悸,乏力,体重下降。她在60岁时因非毒性结节性甲状腺肿行甲状腺全切术,当时无恶变倾向。术后服用左旋甲状腺素100μg/天。她出现心动过速,无颈部肿块和眼部损害,促甲状腺素水平被抑制(0.000μU/ml),游离甲状腺素(3.22ng/dl)和游离三碘甲状腺原氨酸(8.46pg/ml)升高。胸片未发现纵膈增大和气管偏移。患者停用左旋甲状腺素10天后,甲状腺素水平和三碘甲状腺原氨酸水平并无改善。甲状腺球蛋白升至294mg/ml。颈部超声提示无甲状腺残留。抗甲状腺素受体升高至19.7U/l。人体显像提示胸腔内放射性碘摄取增加,CT证实纵膈内有一大小60*40mm肿块。于是开始服用他巴唑10mg/d治疗,3月后甲状腺功能正常,然后行手术切除。病检提示无恶变。

虽然甲状腺全切术后的甲状腺毒症常常是由于补充了过多的甲状腺素,但是甲状腺功能亢进却是很少见的,因此我们应该注意。

原始出处:

Cunha FM,Rodrigues E,Oliveira J,Saavedra A,Vinhas LS,Carvalho D.Graves' Disease in a Mediastinal Mass Presenting After Total Thyroidectomy for Nontoxic Multinodular Goiter.J Med Case Reports. 2016;10(70)

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1782638, encodeId=b2461e8263865, content=<a href='/topic/show?id=cff1413333' target=_blank style='color:#2F92EE;'>#case report#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4133, encryptionId=cff1413333, topicName=case report)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Oct 31 22:16:00 CST 2016, time=2016-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039589, encodeId=33402039589bf, content=<a href='/topic/show?id=7ae88244a6' target=_blank style='color:#2F92EE;'>#Graves#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8244, encryptionId=7ae88244a6, topicName=Graves)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Jun 08 20:16:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027921, encodeId=7221202e9211e, content=<a href='/topic/show?id=7c9a41324e' target=_blank style='color:#2F92EE;'>#case#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4132, encryptionId=7c9a41324e, topicName=case)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Wed Nov 23 23:16:00 CST 2016, time=2016-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88147, encodeId=45fc8814e3b, content=好文章,得多学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Thu Jun 02 02:40:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1464158, encodeId=0f0814641588d, content=<a href='/topic/show?id=9a0982481a' target=_blank style='color:#2F92EE;'>#Graves病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8248, encryptionId=9a0982481a, topicName=Graves病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25146601811, createdName=aliceclz, createdTime=Fri May 27 08:16:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606926, encodeId=f075160692691, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri May 27 08:16:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624778, encodeId=be4c1624e7862, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4120, encryptionId=0333412062, topicName=Cas)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=411420689333, createdName=yaanren, createdTime=Fri May 27 08:16:00 CST 2016, time=2016-05-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1782638, encodeId=b2461e8263865, content=<a href='/topic/show?id=cff1413333' target=_blank style='color:#2F92EE;'>#case report#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4133, encryptionId=cff1413333, topicName=case report)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Oct 31 22:16:00 CST 2016, time=2016-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039589, encodeId=33402039589bf, content=<a href='/topic/show?id=7ae88244a6' target=_blank style='color:#2F92EE;'>#Graves#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8244, encryptionId=7ae88244a6, topicName=Graves)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Jun 08 20:16:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027921, encodeId=7221202e9211e, content=<a href='/topic/show?id=7c9a41324e' target=_blank style='color:#2F92EE;'>#case#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4132, encryptionId=7c9a41324e, topicName=case)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Wed Nov 23 23:16:00 CST 2016, time=2016-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88147, encodeId=45fc8814e3b, content=好文章,得多学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Thu Jun 02 02:40:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1464158, encodeId=0f0814641588d, content=<a href='/topic/show?id=9a0982481a' target=_blank style='color:#2F92EE;'>#Graves病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8248, encryptionId=9a0982481a, topicName=Graves病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25146601811, createdName=aliceclz, createdTime=Fri May 27 08:16:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606926, encodeId=f075160692691, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri May 27 08:16:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624778, encodeId=be4c1624e7862, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4120, encryptionId=0333412062, topicName=Cas)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=411420689333, createdName=yaanren, createdTime=Fri May 27 08:16:00 CST 2016, time=2016-05-27, status=1, ipAttribution=)]
    2016-06-08 xinmeili
  3. [GetPortalCommentsPageByObjectIdResponse(id=1782638, encodeId=b2461e8263865, content=<a href='/topic/show?id=cff1413333' target=_blank style='color:#2F92EE;'>#case report#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4133, encryptionId=cff1413333, topicName=case report)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Oct 31 22:16:00 CST 2016, time=2016-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039589, encodeId=33402039589bf, content=<a href='/topic/show?id=7ae88244a6' target=_blank style='color:#2F92EE;'>#Graves#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8244, encryptionId=7ae88244a6, topicName=Graves)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Jun 08 20:16:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027921, encodeId=7221202e9211e, content=<a href='/topic/show?id=7c9a41324e' target=_blank style='color:#2F92EE;'>#case#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4132, encryptionId=7c9a41324e, topicName=case)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Wed Nov 23 23:16:00 CST 2016, time=2016-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88147, encodeId=45fc8814e3b, content=好文章,得多学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Thu Jun 02 02:40:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1464158, encodeId=0f0814641588d, content=<a href='/topic/show?id=9a0982481a' target=_blank style='color:#2F92EE;'>#Graves病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8248, encryptionId=9a0982481a, topicName=Graves病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25146601811, createdName=aliceclz, createdTime=Fri May 27 08:16:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606926, encodeId=f075160692691, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri May 27 08:16:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624778, encodeId=be4c1624e7862, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4120, encryptionId=0333412062, topicName=Cas)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=411420689333, createdName=yaanren, createdTime=Fri May 27 08:16:00 CST 2016, time=2016-05-27, status=1, ipAttribution=)]
    2016-11-23 charl1234567
  4. [GetPortalCommentsPageByObjectIdResponse(id=1782638, encodeId=b2461e8263865, content=<a href='/topic/show?id=cff1413333' target=_blank style='color:#2F92EE;'>#case report#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4133, encryptionId=cff1413333, topicName=case report)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Oct 31 22:16:00 CST 2016, time=2016-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039589, encodeId=33402039589bf, content=<a href='/topic/show?id=7ae88244a6' target=_blank style='color:#2F92EE;'>#Graves#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8244, encryptionId=7ae88244a6, topicName=Graves)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Jun 08 20:16:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027921, encodeId=7221202e9211e, content=<a href='/topic/show?id=7c9a41324e' target=_blank style='color:#2F92EE;'>#case#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4132, encryptionId=7c9a41324e, topicName=case)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Wed Nov 23 23:16:00 CST 2016, time=2016-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88147, encodeId=45fc8814e3b, content=好文章,得多学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Thu Jun 02 02:40:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1464158, encodeId=0f0814641588d, content=<a href='/topic/show?id=9a0982481a' target=_blank style='color:#2F92EE;'>#Graves病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8248, encryptionId=9a0982481a, topicName=Graves病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25146601811, createdName=aliceclz, createdTime=Fri May 27 08:16:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606926, encodeId=f075160692691, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri May 27 08:16:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624778, encodeId=be4c1624e7862, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4120, encryptionId=0333412062, topicName=Cas)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=411420689333, createdName=yaanren, createdTime=Fri May 27 08:16:00 CST 2016, time=2016-05-27, status=1, ipAttribution=)]
    2016-06-02 沉心多思

    好文章,得多学习了!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1782638, encodeId=b2461e8263865, content=<a href='/topic/show?id=cff1413333' target=_blank style='color:#2F92EE;'>#case report#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4133, encryptionId=cff1413333, topicName=case report)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Oct 31 22:16:00 CST 2016, time=2016-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039589, encodeId=33402039589bf, content=<a href='/topic/show?id=7ae88244a6' target=_blank style='color:#2F92EE;'>#Graves#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8244, encryptionId=7ae88244a6, topicName=Graves)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Jun 08 20:16:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027921, encodeId=7221202e9211e, content=<a href='/topic/show?id=7c9a41324e' target=_blank style='color:#2F92EE;'>#case#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4132, encryptionId=7c9a41324e, topicName=case)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Wed Nov 23 23:16:00 CST 2016, time=2016-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88147, encodeId=45fc8814e3b, content=好文章,得多学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Thu Jun 02 02:40:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1464158, encodeId=0f0814641588d, content=<a href='/topic/show?id=9a0982481a' target=_blank style='color:#2F92EE;'>#Graves病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8248, encryptionId=9a0982481a, topicName=Graves病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25146601811, createdName=aliceclz, createdTime=Fri May 27 08:16:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606926, encodeId=f075160692691, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri May 27 08:16:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624778, encodeId=be4c1624e7862, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4120, encryptionId=0333412062, topicName=Cas)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=411420689333, createdName=yaanren, createdTime=Fri May 27 08:16:00 CST 2016, time=2016-05-27, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1782638, encodeId=b2461e8263865, content=<a href='/topic/show?id=cff1413333' target=_blank style='color:#2F92EE;'>#case report#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4133, encryptionId=cff1413333, topicName=case report)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Oct 31 22:16:00 CST 2016, time=2016-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039589, encodeId=33402039589bf, content=<a href='/topic/show?id=7ae88244a6' target=_blank style='color:#2F92EE;'>#Graves#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8244, encryptionId=7ae88244a6, topicName=Graves)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Jun 08 20:16:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027921, encodeId=7221202e9211e, content=<a href='/topic/show?id=7c9a41324e' target=_blank style='color:#2F92EE;'>#case#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4132, encryptionId=7c9a41324e, topicName=case)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Wed Nov 23 23:16:00 CST 2016, time=2016-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88147, encodeId=45fc8814e3b, content=好文章,得多学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Thu Jun 02 02:40:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1464158, encodeId=0f0814641588d, content=<a href='/topic/show?id=9a0982481a' target=_blank style='color:#2F92EE;'>#Graves病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8248, encryptionId=9a0982481a, topicName=Graves病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25146601811, createdName=aliceclz, createdTime=Fri May 27 08:16:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606926, encodeId=f075160692691, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri May 27 08:16:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624778, encodeId=be4c1624e7862, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4120, encryptionId=0333412062, topicName=Cas)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=411420689333, createdName=yaanren, createdTime=Fri May 27 08:16:00 CST 2016, time=2016-05-27, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1782638, encodeId=b2461e8263865, content=<a href='/topic/show?id=cff1413333' target=_blank style='color:#2F92EE;'>#case report#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4133, encryptionId=cff1413333, topicName=case report)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Oct 31 22:16:00 CST 2016, time=2016-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039589, encodeId=33402039589bf, content=<a href='/topic/show?id=7ae88244a6' target=_blank style='color:#2F92EE;'>#Graves#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8244, encryptionId=7ae88244a6, topicName=Graves)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Jun 08 20:16:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027921, encodeId=7221202e9211e, content=<a href='/topic/show?id=7c9a41324e' target=_blank style='color:#2F92EE;'>#case#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4132, encryptionId=7c9a41324e, topicName=case)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Wed Nov 23 23:16:00 CST 2016, time=2016-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88147, encodeId=45fc8814e3b, content=好文章,得多学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Thu Jun 02 02:40:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1464158, encodeId=0f0814641588d, content=<a href='/topic/show?id=9a0982481a' target=_blank style='color:#2F92EE;'>#Graves病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8248, encryptionId=9a0982481a, topicName=Graves病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25146601811, createdName=aliceclz, createdTime=Fri May 27 08:16:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606926, encodeId=f075160692691, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri May 27 08:16:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624778, encodeId=be4c1624e7862, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4120, encryptionId=0333412062, topicName=Cas)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=411420689333, createdName=yaanren, createdTime=Fri May 27 08:16:00 CST 2016, time=2016-05-27, status=1, ipAttribution=)]
    2016-05-27 yaanren

相关资讯

JCEM:抗甲状腺药物治疗GD复发率高

有多种治疗方案可用于Graves病(GD),包括抗甲状腺药物(ATDs)、放射性碘(RAI)和甲状腺切除术。为了确定各种治疗方案的复发率,以及现有的关于ATDs不良反应的数据,来自美国马约诊所Rebecca S Bahn教授及其团队进行了一项研究,该研究发现ATDs治疗GD复发率高。该研究结果在线发表在2013年7月3日的《临床内分泌代谢杂志》(The journal of clinical en

Clin Endocrinol:硒缺乏或与Graves病有关

硒缺乏可能在自身免疫性甲状腺疾病的发生和发展中发挥重要作用。为了在丹麦新诊断自身免疫性甲状腺疾病患者和对照受试者中比较血清硒含量(S–Se),来自丹麦奥尔胡斯大学奥尔堡医院Inge Bülow Pedersen教授及其团队进行了一项研究,该研究发现新诊断GD患者和AIH患者的S–Se显著低于随机对照者。该研究结果发表在2013年10月Clinical Endocrinolo

Thyroid:病毒感染或参与Graves病起病

不同GD患者甲状腺组织CD4+和CD8+ T细胞、以及浆细胞的比较 极少有研究系统性调查Graves病起始时免疫细胞渗入甲状腺组织。病毒在自身免疫性甲状腺疾病发病机制中的作用仍有争议。为了分析Graves病患者病毒感染迹象有关的炎症反应,来自挪威奥斯陆大学附属医院Sara Salehi Hammerstad教授及其团队进行了一项研究,该研究发现长期GD期间CD8+ T细胞增加,GD早期MxA

Baidu
map
Baidu
map
Baidu
map